Interview: Enrico Allievi – Director, Assosalute, Italy
Enrico Allievi, President of the Italian OTC (Over The Counter) association, Assosalute, talks about the state of the OTC market in Italy, as well as the association’s role in creating…
Address: Via C. Colombo 1, I – 20020 Lainate,Italy
Tel: +39 02 9333 7614
Web: http://www.cosmopharmaceuticals.com/
Cosmo is a specialty pharmaceutical company that aims to become a global leader in the market of optimized therapies for selected gastro-intestinal diseases. The company’s proprietary clinical development pipeline specifically addresses innovative treatments for the gastro-intestinal tract, specifically Inflammatory Bowel Diseases (IBD), colon infections and colon diagnosis, as well as selected topically treated Skin Disorders.
Cosmo’s lead product Lialda®, the first product based on MultiMatrix Technology (‘MMX®’), was launched into the US market by Shire Pharmaceuticals plc on 19 March 2007. Another product, a nutraceutical, Zacol NMX®, is marketed in Italy and selected Eastern European countries. In addition the company has five pharmaceutical product candidates for the colon: Budesonide MMX® which has successfully completed phase III and has been filed for registration in the EU and US, Rifamycin SV MMX® which is in clinical phase III, LMW Heparin MMX® in phase II, Naloxon MMX®, which is in phase I and Blue Methylene MMX® which is in phase II. These products will address unmet needs in the diagnosis and treatment of colon diseases. This market is expected to grow, primarily because old and less effective products will be replaced by more effective ones. CB-03-01, the first new chemical entity the Company is developing is targeted at the acne, hirsutism and alopecia market and is presently in phase II.
Cosmo’s proprietary MMX® technology is at the core of the company’s product pipeline and was developed from its expertise in formulating and manufacturing gastro-intestinal pharmaceutical products for international clients at its GMP (Good Manufacturing Practice) facilities in Lainate, Italy.
Cosmo has a deep and broad expertise in the development of gastro-intestinal (GI) pharmaceutical products with a specific focus on Inflammatory Bowel Disease, based on the company’s innovative and proprietary MMX® technology. Most recently the Company has extended its expertise to other colon applications and to skin disorders where it is developing a new molecule.
The Company has built a successful and profitable pharmaceutical manufacturing business manufacturing products for international companies and in 2006 trebled its manufacturing capacity by adding a state-of-the-art, FDA-approved plant (for the production of Lialda®/Mezavant®), intended for the manufacturing of its own products.
The company’s proprietary MMX® technology is at the core of the product pipeline and was developed from its expertise in formulating and manufacturing GI pharmaceutical products for international clients. The research led to new patents that increased the efficacy of existing pharmaceutical products by modifying their formulations and tailoring their optimized delivery systems.
Enrico Allievi, President of the Italian OTC (Over The Counter) association, Assosalute, talks about the state of the OTC market in Italy, as well as the association’s role in creating…
Dr. Anna Maria Porrini, President of Boehringer Ingelheim Italy shares her vision for the company, how she intends to achieve it and where she sees opportunities for the company’s success…
Antonino Reale, who has managed Daiichi-Sankyo Italy for the last 12 years, explains the reasoning and strategy behind the company’s almost total restructuring in 2013, including how this has given…
Gabriele Baccelli shares his journey of setting up a lean organization at a time of crisis, the management decisions he took in order to navigate this environment and how he…
The Italian Medicines Agency, AIFA, sits at a crossroads. Its Director-General Prof. Luca Pani discusses the apparent contradiction in the agency’s mission at a time of constricting budgets and expensive…
Thibaud Eckenschwiller, VP & Managing Director for Ipsen Italy, shares his impression of the Italian pharmaceutical market after one year in office, how he is applying Ipsen’s global strategy to…
Alessandra Modenese Kauffmann, General Manager of the Swiss Chamber of Commerce, shares her insights into the relationship between Italy and Switzerland, the Chamber’s efforts to foster trade between the two…
Massimiliano Rocchi, Managing Director at Accord Italy shares his view on the story behind Accord’s success in Europe, the key differentiating elements for any generics company in a market with…
Massimo Scaccabarozzi, President of Farmindustria, talks about the potential of the pharmaceutical industry in Italy, the changes which need implementing to realize that potential and his vision for the industry’s…
Leonardo Vingiani, Director of Assobiotec, discusses how the country’s biotech industry has evolved since 2009, what areas still need improving and the enormous progress which has been made in unlocking…
Jörg Buck, the Executive Director of the Italian-German Chamber of Commerce discusses the close trade relationship which ties the two countries together, how the business environment in Italy is evolving…
Sicily plays a major role in a plethora of gangster stories, whether real or fictional; the initiated also know that it is the land of incredibly well preserved Greco-Roman sights…
See our Cookie Privacy Policy Here
